DocDollars

Takeda Pharmaceuticals U.S.A., Inc.

MA · United States · Reporting entity ID 100000000337

Total reported 2019–2025
$1.45B
#14 of 2,960 reporting companies — 1.7% of all reported industry payments
$621.9M in general payments across 1,090,120 records, plus $830.3M in research funding across 101,869 records.

How it breaks down

General payments $621,870,746
Research funding $830,260,405

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Takeda Pharmaceuticals U.S.A., Inc. reported $1.45B to US doctors and teaching hospitals from 2019 to 2025, ranking #14 of 2,960 reporting companies. 57% of that was research funding and 43% general payments such as consulting, speaking, food and travel. 1,090,120 general payment records and 101,869 research records were filed.

Common questions about Takeda Pharmaceuticals U.S.A., Inc.

How much has Takeda Pharmaceuticals U.S.A., Inc. paid US doctors?

Takeda Pharmaceuticals U.S.A., Inc. reported $1,452,131,151 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $621,870,746 in general payments, $830,260,405 in research funding.

How does Takeda Pharmaceuticals U.S.A., Inc. rank among drug and device companies?

It ranks #14 of 2,960 reporting entities by total reported value, about 1.7% of all industry payments in the dataset.

Does a payment from Takeda Pharmaceuticals U.S.A., Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.